Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2007

View Archived Issues

PARP inhibition may be beneficial in retinitis pigmentosa / News in Context

Latest findings reported for therapeutic agents under development for treatment of plaque psoriasis

Preclinical data on two novel PPAR modulators from Pierre Fabre

Inhibition of integrin alpha5beta1 may be useful in treating ocular neovascularization

Alizyme provides update on phase III programs

Novacea initiates phase II trial with AQ4N for ALL

BioCryst begins patient enrollment in pivotal forodesine trial

Threshold stops enrollment in phase II trial of glufosfamide

MedImmune and Crucell develop new antibodies for hospital-acquired bacterial infection

Neuron and Metabolic select NRP compound with therapeutic potential

Promising phase II data reported from ASA-404 phase II trial

Sanofi Pasteur and Institut Pasteur to codevelop malaria vaccine

AMDL seeks FDA approval for ELISA tumor marker test

Novel treatment option for drug addiction disclosed by State University of New York

Orexo to acquire Biolipox

Bristol-Myers Squibb licenses SARM program to Pharmacopeia

Disappointing phase II data reported for MEM-1003

Expansion cohort in phase I Hedgehog antagonist trial initiated by Genentech

FDA approves IND for CA9-SCAN pivotal phase III trial

FDA grants orphan drug status for tamibarotene in acute promyelocytic leukemia

Neuromed concludes SPA with FDA for a pivotal phase III NMED-1077 trial

Wyeth and Progenics initiate phase II oral methylnaltrexone trials

Pivotal phase III Zingo trial meets primary endpoint

Novel class I HDAC inhibitor developed at Merck & Co.

Recent patents disclose novel anxiolytic, antidepressant and antipsychotic agents

Only FDA-approved anthracycline extravasation kit reaches market

Study suggests feasibility of vaccine prevention of maternal CMV infection

Recent Bayer Schering Pharma patents report novel agents for male contraception

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...